Exploiting Recurrent Chromatin Modifier Mutations for Prostate Cancer Targeted Therapy
Abstract
This research project is designed to test the hypothesis that mutations in different chromatin-modifying (CM) enzymes result in similar effects on the cell because they feed into the same biological processes and pathways that promote cell survival, cell growth, and resistance to treatment. A corollary of this hypothesis is that different tumors, with mutations in different chromatin-modifying enzymes, can be targeted by the same therapy designed to reverse or suppress the downstream effects of these mutations. In Aim 1 of our proposal, we will identify the chromatin-modifying genes whose loss leads to therapy resistance and determine how those factors are related to each other. In Aim 2, we will investigate the biological basis of this resistance by measuring global changes to gene regulation. Lastly, in Aim 3 we will devise a therapeutic strategy to be used alongside androgen blockade- specifically in PCs that harbor alterations in genes that modify or interact with chromatin.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2020
- Accession Number
- AD1114610
Entities
People
- Michael D. Nyquist
Organizations
- Fred Hutchinson Cancer Center